October 2020.
elong.Life has expanded its digital clinical trial matching program to include patients with multiple sclerosis (MS). The technology uses advanced artificial intelligence (AI) that processes a patient’s medical data and determines which trials in its global database are appropriate. The app typically returns results, which are prescreened by a clinical trial coordinator, in less than two days. More than 8,000 cancer patients have used the program so far.
Belong.Life is a global leader in digital health, revolutionizing the patient experience and delivering unparalleled value for patients, healthcare providers, pharmaceutical companies, and payers.
Belong’s key solutions include the world’s largest social and professional networks for people living with cancer (Belong – Beating Cancer Together) and multiple sclerosis (BelongMS), and the BelongAI health-grade patient engagement and support platforms including Dave AI Cancer Mentor medically validated by renowned oncologists at ASCO and ESMO, Sophie– AI MS Mentor, Tara – AI Clinical Trials Matching Assistant and Fred – AI Weight and Health Mentor, which utilizes AI to proactively support and empower patients throughout their healthcare journey.
